Primatene Mist is an aerosol, metered;inhalation drug owned by Armstrong Pharms. It contains the active ingredient, epinephrine. The drug was first authorized for market use on 07 November, 2018. Currently, Primatene Mist holds a total of 1 patent and none of these patents have expired.
The last patent of Primatene Mist will expire on 26 January, 2026. Thus, the potential for the entry of Primatene Mist generic drugs into the market is expected to be possible post this date. The specific patent impacting the release date of generic versions is US8367734, with the title: 'Stable epinephrine suspension formulation with high inhalation delivery efficiency.'
Primatene Mist is primarily used for its active ingredient, epinephrine, known for its high inhalation delivery efficiency. epinephrine plays a crucial role in treating conditions such as asthma, cardiac arrest, and severe allergic reactions. Its stability in suspension formulation contributes significantly to its therapeutic effectiveness.
Primatene Mist holds a single patent - US8367734, titled 'Stable epinephrine suspension formulation with high inhalation delivery efficiency.' The expiration of this patent on 26 January, 2026, marks the potential entry point for Primatene Mist generic version. Below are the details of the patent: